

GENETIC THERAPY

EVENT SERIES
2024

BROUGHT TO YOU BY

hansonwade

FROM PROMISE TO REALITY: DELIVERING SAFER, MORE EFFECTIVE, & GLOBALLY ACCESSIBLE GENETIC THERAPIES TO PATIENTS

Gene therapies are redefining the treatment of a host of devastating diseases, giving hope to patients who previously had no therapeutic options.

We share a common belief with the industry: the potential of gene therapies is enormous. In the battle against rare diseases and beyond, gene therapies can be transformative and the right insights and connections will sharpen the weapons that are in your arsenal.

The Gene Therapy team remains committed to providing a unique platform, uniting biopharma's decision makers and the right solution providers, to help them tackle the most pressing challenges in order to commercialize candidate in 2024.

We pride ourselves on our market-leading conferences, giving you access to a global, selected KOLs in the gene therapy space.

Working with the Gene Therapy team will provide you with an environment specifically tailored to enable you to generate new relationships with decision makers and elevate your brand awareness within gene therapy

MEET THE TEAM

Alice Maynes
Portfolio Director

Nick Mayne
Senior Program Director

Niamh Rowe
Program Director

Jessica Marriott
Program Director

Max Falk
Program Director

Thomas Stockdale
Partnerships Director

Max Wainwright
Partnerships Director

Olivia Bull
Senior Marketing Manager

Karina Bikerniece
Marketing Manager

Rachel McMahon
Marketing Executive

THE NUMBERS THAT MATTER

Attendees Across The Series

450+
Expert speakers

75%
Large pharma and biotech

64%
Director and above

Gene Therapy Regulatory Affairs
genetherapy-regulatory.com
January 23-25, 2024 | Boston

4th Annual Gene Therapy Comparability
genetherapy-comparability.com
February 13-15 | Boston

2nd Annual Viral Vector Process Development & Manufacturing Summit
viral-vector-process-development.com
February 20-22, 2024 | Boston

7th Annual Gene Therapy for Rare Disorders
genetherapy-conference.com
March 26-29, 2024 | Boston

4th Annual Gene Therapy for Muscular Disorders
genetherapy-muscular.com
April 16-18, 2024 | Boston

5th Annual Gene Therapy Analytical Development Europe
genetherapy-analytical-europe.com
May 22-24, 2024 | London

4th Annual Gene Therapy Patient Engagement
genetherapy-patient-engagement.com
May 29-31, 2024 | Boston

2nd Annual Viral Vector Formulation & Process Development Summit EUROPE
viral-vector-process-development-europe.com
June 4-6, 2024 | Amsterdam

4th Annual Next Generation Gene Therapy Vectors
next-gen-genetherapy-vectors.com
June 11-13, 2024 | Boston

2nd Annual Gene Therapy Potency Assay
genetherapy-potency-assay.com
July 16-18, 2024 | Boston

5th Annual Gene Therapy Immunogenicity
genetherapy-immunogenicity.com
August 20-22, 2024 | Boston

2nd Annual CRISPR ANALYTICAL DEVELOPMENT
crispr-analytical-development.com
September 4-6, 2024 | Boston

5th Annual Exosome Based Therapeutic Development Summit
exosomebased-therapeutics.com
September 10-12, 2024 | Boston

5th Annual Gene Therapy for Ophthalmic Disorders
genetherapy-ophthalmology.com
October 1-3, 2024 | Boston

6th Annual Gene Therapy Analytical Development
genetherapy-analytical.com
November 5-8, 2024 | Boston

5th Annual CRISPR2.0
crispr-conference.com
November 26-28, 2024 | Boston

6th Annual Gene Therapy for Neurological Disorders
genetherapy-neurological.com
December 2-4, 2024 | Boston

2nd Annual Gene Therapy Process Development
genetherapy-process-development.com
December 10-12, 2024 | Boston

*Exact dates subject to change

7th Annual

Gene Therapy for Rare Disorders

Gene therapies are redefining the treatment of rare diseases. However, as the field looks to turn these transformative therapies into a commercial reality, unique challenges must be overcome for these therapeutics to deliver on their potential.

The Gene Therapy for Rare Disorders meeting is dedicated solely to tackling late-stage manufacturing, clinical, regulatory and commercial challenges as companies look to prioritize their late-stage gene therapy assets.

Attendee Breakdown

Attendee Seniority

- C Level 17%
- VP 19%
- Director 34%
- Manager 8%
- Scientist 5%
- Other 17%

Industry Breakdown

- Pharma 18%
- Biotech 50%
- Not for Profit 6%
- Academic 7%
- Contract Service Provider 12%
- Other 7%

80+ SPEAKERS

200+ COMPANIES

400+ ATTENDEES

68% LARGE PHARMA & BIOTECH

"Best conference of the year for gene therapy companies to understand how our industry is tackling the challenges of pioneering the development of our advanced therapy products"

Benjamin Dewees, Senior Director, Regulatory Affairs, **Sangamo Therapeutics**

Snapshot of Attending Companies

Alliance for Regenerative Medicine · Amicus Therapeutics · Novartis · AVROBIO

Biogen · BioMarin · CSL Behring Biotherapies for Life™ · Lilly

European Medicines Agency · FDA · Freeline · GSK

Homology Medicines, Inc. · LYSOGENE · Neurocrine Biosciences · NORD National Organization for Rare Disorders

Beam Therapeutics · novo nordisk® · Orchard therapeutics · Pfizer

REGENERON · REGENXBIO · Roche · Sangamo Therapeutics

SANOFI · SAREPTA THERAPEUTICS · SOLID BIOSCIENCES · Spark Therapeutics

6th Annual
Gene Therapy Analytical Development

5th Annual
Gene Therapy Analytical Development Europe

The design, validation, and implementation of increasingly complex analytics are needed to support the wave of gene therapies moving through the clinic and towards approval.

The Gene Therapy Analytical Development meetings unite Analytical Development, QC, CMC and Process Development leaders to discuss the full and comprehensive range of analytical tools required to guarantee the consistency, quality and safety of gene therapy products.

Attendee Breakdown



Attendee Seniority

- C Level 10%
- VP 5%
- Director 23%
- Manager 14%
- Scientist 31%
- Other 17%



Industry Breakdown

- Pharma 31%
- Biotech 36%
- Not for Profit 3%
- Academic 4%
- Contract Service Provider 22%
- Other 4%

100+ SPEAKERS

200+ COMPANIES

650+ ATTENDEES

67% LARGE PHARMA & BIOTECH

4

"A great opportunity to assess the landscape of analytical methodology currently employed by other firms engaged in gene therapy development and identify where emerging technologies are going."

Clement Purcell, Analytical Project Leader, Principal Fellow - Cell & Gene Therapies, **Novartis**

Snapshot of Attending Companies

ADVERUM BIOTECHNOLOGIES · Allergan · NOVARTIS · SIO GENE THERAPIES

BAYER · BIOMARIN · bluebirdbio · Bristol Myers Squibb

CARIBOU BIOSCIENCES · Decibel THERAPEUTICS · Dyno Therapeutics · Encoded THERAPEUTICS

flexion · IVERIC bio · JUNO | Bristol Myers Squibb Company · Kite A GILEAD Company

LEGEND BIOTECH · LogicBio THERAPEUTICS · MEIRAGTx · Beam THERAPEUTICS

Prevail THERAPEUTICS · ring THERAPEUTICS A Flagship Pioneering Company · Sangamo THERAPEUTICS · Selecta Biosciences

SwanBio THERAPEUTICS · Takeda · uniQure · Voyager THERAPEUTICS

6th Annual

Gene Therapy for Neurological Disorders

Gene Therapy for Neurological Disorders is dedicated to solving the translational drug development and delivery challenges of targeting the CNS.

Improve the translatability of small and large animal models, develop innovative delivery approaches to guarantee delivery of vectors and understand the realities of immunogenicity challenges in the CNS.

Attendee Breakdown

Attendee Seniority

- Chief/CXO....16%
- Director....30%
- Head....17%
- Manager....5%
- President/VP....21%
- Other....11%

Industry Breakdown

- Drug Developers....49%
- Academic & Research Institutions....26%
- Service Providers & Other....25%

30+ SPEAKERS

60+ COMPANIES

100+ ATTENDEES

64% LARGE PHARMA & BIOTECH

4

"Absolutely brilliant"

Shephard Mpofu
Senior Vice President & Chief Medical Officer
Novartis Gene Therapies

Snapshot of Attending Companies

abbvie · ACADIA Pharmaceuticals · askbio · astellas · AUDENTES Therapeutics · NOVARTIS · axovant Gene Therapies · Biogen · BIOMARIN · Eisai · Genentech A Member of the Roche Group · Lundbeck · MEIRAGTx · MERCK · Pfizer · Prevail Therapeutics · PTC Therapeutics · REGENXBIO · Roche · SANOFI · SAREPTA Therapeutics · SOLID Biosciences · Spark Therapeutics · Takeda · UCB · uniQure · VERTEX · Voyager Therapeutics

5th Annual

Gene Therapy for Ophthalmic Disorders

Gene Therapy for Ophthalmic Disorders is dedicated to solving the delivery and drug development challenges encountered with targeting the eye.

Industry pioneers from the leading pharma and biotech companies will share how to deliver therapies effectively to the back of the eye, pursue novel clinical endpoints that meet regulatory expectations and enhance the next generation of safe and effective viral and non-viral vectors.

Attendee Breakdown



Attendee Seniority

- C Level 27%
- VP 15%
- Director 21%
- Manager/Head 14%
- Scientist 10%
- Other 13%

Industry Breakdown

- Biotech 58%
- Pharma 18%
- Service Provider 11%
- Academic 9%
- Other 4%

30+ SPEAKERS

75+ COMPANIES

150+ ATTENDEES

90% LARGE PHARMA & BIOTECH

4

"Very efficiently organized-excellent speakers"

Patricia Zilliox
Chief Executive Officer
Eyevensys

Snapshot of Attending Companies

ADVERUM BIOTECHNOLOGIES · Apellis · Biogen · Boehringer Ingelheim · CHUGAI · EMENDO BIOTHERAPEUTICS · eyevensys · FDA · FRONTERA THERAPEUTICS · Genentech A Member of the Roche Group · GYROSCOPE VISION FOR LIFE · HOMOLOGY Medicines, Inc. · janssen · MEIRAGTx · NOVARTIS · ocugen · OMEGA THERAPEUTICS · PYC THERAPEUTICS · REGENXBIO · Roche · SANOFI · Santen · SIO GENE THERAPIES · Spark THERAPEUTICS

4th Annual

Gene Therapy for Muscular Disorders



Gene Therapy for Muscular Disorders aims to revolutionize muscular gene therapy development by enabling successful targeting and transduction of the muscle whilst mitigating toxicity.

This event will showcase state-of-the-art discovery research to optimally target and transduce muscle cells, as well as clinical challenges facing more advanced programs, to successfully develop and safely deliver the optimal dose to their muscular targets.

Attendee Breakdown



Attendee Seniority

- C Level 18%
- VP 25%
- Director 32%
- Manager 15%
- Scientist 10%



Industry Breakdown

- Pharma 22%
- Biotech 45%
- Not for Profit 8%
- Academic 5%
- Contract Service Provider 15%
- Other 5%

30+ SPEAKERS

40+ COMPANIES

100+ ATTENDEES

72% LARGE PHARMA & BIOTECH

4

"The conference overall expanded my knowledge in gene therapy targeting muscle diseases but also offered additional learning in the areas of immunology and redosing strategies."

Paul Fitzpatrick
Senior Director, Bioprocess Technology, **Zogenix**

Snapshot of Attending Companies

ALEXION · Amicus Therapeutics · astellas · AUDENTES An Astellas Company

Biogen · BIOMARIN · bridgebio · Bristol Myers Squibb

code bio · Cure Duchenne · DNAQOR · Dyno Therapeutics

GENETHON · moderna messenger therapeutics · NOVARTIS · Pfizer

PRECISION BIOSCIENCES · PTC THERAPEUTICS · REGENERON · REGENXBIO

Roche · SAREPTA THERAPEUTICS · SOLID BIOSCIENCES · VERTEX

5th Annual

Gene Therapy Immunogenicity

Gene Therapy Immunogenicity seeks to address the complex challenges of immunogenicity, so that drug developers can more confidently measure, modulate and predict immune response to their gene therapy candidates.

Bringing together decision-makers from the industry to tackle key immunogenicity roadblocks facing end-to-end drug development, this meeting aims to collaboratively overcome the fields challenges and find improved solutions.

Immunogenicity is one of the greatest safety challenges facing gene therapy drug developers and they need the expertize of solution providers to help drive their candidates through the clinic and beyond.

Attendee Breakdown

Attendee Seniority

- C Level 7%
- VP 15%
- Director 33%
- Head 9%
- Scientist 28%
- Other 8%

Industry Breakdown

- Biotech 52%
- Pharma 23%
- service Provider 15%
- Academic 10%

25+ SPEAKERS

50+ COMPANIES

150+ ATTENDEES

85% LARGE PHARMA & BIOTECH

"Inspiring virtual meeting allowing efficient learning about the most recent advances in gene therapy immunogenicity while still having interactions with peers."

Cornelia Ciorciaro
Director - Safety Science
Group Medical, **Roche**

Snapshot of Attending Companies

ADVERUM BIOTECHNOLOGIES · affinia THERAPEUTICS · ALLYX THERAPEUTICS
BAYER · BIOMARIN · bridgebio
CHAMELEON BIOSCIENCES INC · CIRCUIT THERAPEUTICS · CODA BIOTHERAPEUTICS
Dyno Therapeutics · Encoded THERAPEUTICS · FDA
FREELINE · HOMOLOGY Medicines, Inc. · KRIYA THERAPEUTICS™
novo nordisk® · NOVARTIS · Pfizer
REGENERON · Roche · Selecta Biosciences
SOLID BIOSCIENCES · Takeda · ucb

4th Annual

Gene Therapy Comparability

As drug developers are increasingly prioritizing their later stage assets and bringing them through to approval, the Gene Therapy Comparability Summit will unite large pharma and innovative biotechs to ensure you can establish comparability at every stage of development, supporting a seamless transition to the larger scales required for commercialization.

Focused specifically on enhancing gene therapy comparability approaches, this event will ensure you can maintain safety, quality, consistency and efficacy while adapting manufacturing processes, methods and platforms, to ensure you satisfy regulatory demands and avoid costly delays to clinical programs.

Attendee Breakdown



Attendee Seniority

- Chief/CXO..... 6%
- Director..... 36%
- Head..... 5%
- Manager..... 11%
- President..... 10%
- Scientist..... 17%
- Other..... 15%



Industry Breakdown

- Drug Developers..... 69%
- Academic & Research Institutes..... 14%
- Service Providers & Others..... 17%

20+ SPEAKERS

80+ COMPANIES

100+ ATTENDEES

79% LARGE PHARMA & BIOTECH

4

"It was a very informative conference with content that reinforced my current understandings for a successful comparability exercise and provided additional resources as well"

Wendy Larson
Associate Director, Regulatory Affairs, CMC,
BlueRock Therapeutics

Snapshot of Attending Companies

Adaptimmune · ADVERUM BIOTECHNOLOGIES · agtc · Allergan
Amicus Therapeutics · astellas · AstraZeneca · AVROBIO
BAYER · Biogen · BIOMARIN · Genentech A Member of the Roche Group
GILEAD · HOMOLOGY Medicines, Inc. · iVERIC bio · janssen
LYSOGENE · NEUROGENE · NOVARTIS · PassageBio
Pfizer · Roche · FDA · Takeda

4th Annual

Next Generation Gene Therapy Vectors

The Next Generation Gene Therapy Vectors Summit specifically focuses on overcoming the current immunogenicity, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior viral and non-viral delivery vectors.

Spanning a range of delivery approaches from cutting-edge AAV capsid optimisation, utilising lenti and other viral vectors, to innovative non-viral gene therapy approaches, this comprehensive event will enable you to reduce immunogenicity, improve tissue targeting, simplify manufacturing and enhance the safety profile of your approach.

Attendee Breakdown

Attendee Seniority

- C Level 17%
- VP 19%
- Director 34%
- Other 17%
- Manager 8%
- Scientist 5%

Industry Breakdown

- Pharma 18%
- Biotech 50%
- Not for Profit 6%
- Academic 7%
- Contract Service Provider 12%
- Other 7%

25+ SPEAKERS

50+ COMPANIES

100+ ATTENDEES

73% LARGE PHARMA & BIOTECH

4

"Attending this was a very good use of my time. The contextual information and the new data presented by the speakers, along with the discussions that included the moderator and the audience were beyond expectation"

Gary Davis
Research & Development Fellow, **MilliporeSigma**

Snapshot of Attending Companies

4basebio · 4DMT · AAVnerGene (Together, We Find the Cures.) · ADVERUM BIOTECHNOLOGIES

Biogen · Boehringer Ingelheim · CAPSIDA BIOTHERAPEUTICS · CHAMELEON BIOSCIENCES INC.

Decibel THERAPEUTICS · Dyno Therapeutics · elevatebio · FREELINE

generation bio · GYROSCOPE VISION FOR LIFE · iVERIC bio · LogicBio THERAPEUTICS

MEIRAGTx · Neurocrine BIOSCIENCES · Otsuka · PassageBio

Pfizer · REGENERON · TENAYA THERAPEUTICS · SwanBio THERAPEUTICS

4th Annual

Gene Therapy Patient Engagement

As investment in gene therapies continues to grow rapidly, more effectively engaging patients throughout development has become a priority for any company serious about building safer and more meaningful gene therapy programs.

This dedicated summit unites patient advocacy & engagement leaders from gene therapy and gene editing drug developers, patient groups and patients themselves to address the specific challenges of genetic therapy patient engagement, generating actionable insights through detailed case studies and open, honest discussions.

Attendee Breakdown



Attendee Seniority

- C Level 10%
- VP 21%
- Director 46%
- Manager 21%
- Other 2%



Industry Breakdown

- Pharma 23%
- Biotech 44%
- Not for Profit 18%
- Academic 2%
- Contract Service Provider 12%
- Other 2%

20+ SPEAKERS

60+ COMPANIES

80+ ATTENDEES

67% LARGE PHARMA & BIOTECH

4

"A very valuable experience, where I saw behind the curtain in terms of patient advocacy, and gained some insights into a part of the industry to which I hadn't been previously exposed."

Sarah Samaroo Scull
Director, Biomedical Content,
One World DMG

Snapshot of Attending Companies

4DMT · Abeona Therapeutics · Amicus Therapeutics · agtc

askbio · Audentes Therapeutics · Bayer · BioMarin

bluebirdbio · Bristol Myers Squibb · casimir · CRISPR Therapeutics

CSL Behring · GenSight Biologics · gsk · LysoGene

MeiraGTx · moderna · NORD · Novartis

PassageBio · Pfizer · Sangamo · Sanofi

2nd Annual

Gene Therapy Process Development

As gene therapy developers strive to platform their process development to develop therapies more quickly and cost-effectively, optimizing upstream processes has never been a greater priority.

Confounded by shortened timelines and heavy investment into process development from drug developers and CDMOs, the ability to establish repeatable and scalable processes is now a must for all gene therapy developers.

Geared towards those working in upstream process development, molecular biology and manufacturing associates and engineers, bridge the gap between R&D and process development to ensure a high-quality product is manufactured repeatably, at scale, in a cost-effective manner.

Attendee Breakdown

Attendee Seniority

- Cheif/CXO..... 2%
- Director..... 25%
- Head..... 4%
- Manager..... 11%
- Scientist..... 36%
- President/VP..... 2%
- Professor..... 0.5%
- Project/Team .. 1.5%
- Other..... 18%



Industry Breakdown

- Biotech..... 65%
- Pharma..... 20%
- Service Provider..... 12%
- Other..... 2%
- Academics..... 1%

16+ SPEAKERS

40+ COMPANIES

60+ ATTENDEES

77% LARGE PHARMA & BIOTECH

4

"I am excited for networking opportunities with fellow industry experts and learn about how other companies are advancing their platforms"

Jun Li
Associate Director, Upstream Process Development,
Ultragenyx

Snapshot of Attending Companies

AMGEN

astellas

CARBON BIOSCIENCES

The James
The Ohio State University Comprehensive Cancer Center

janssen

Lacerta therapeutics

MEIRAGTx

REGENXBIO

UMass Chan Medical School

ultragenyx

Gene Therapy Program — Perelman School of Medicine, University of Pennsylvania

Vesigen Therapeutics

2nd Annual

Gene Therapy Potency Assay

Potency is the most pressing analytical challenge for gene therapies, and under increasing regulatory scrutiny, potency data packages must be more robust than ever before.

The Gene Therapy Potency Assay Summit unites analytical, bioassay, QC, regulatory and CMC experts to tackle the industries greatest potency challenges. Combining technical data heavy content with strategic case study-based sessions, this forum provides the tools to identify, characterize and measure potency and take actional insights back to the team. This includes sharing learnings on phase appropriate potency assay development, statistical analysis of data packages, utilising matrix approaches, phasing out early-stage assays, method transfer and regulatory feedback from the pre-clinical stage through to commercialization.

Attendee Breakdown



Attendee Seniority

- C Level 11%
- VP 23%
- Director 43%
- Manager 7%
- Scientist 16%



Industry Breakdown

- Pharma 22%
- Biotech 50%
- Academic 8%
- Service Provider 10%
- Not for Profit 7%
- Regulator 3%

20+ SPEAKERS

60+ COMPANIES

100+ ATTENDEES

82% LARGE PHARMA & BIOTECH

4

"Great personnel working the event and wonderful speakers! Overall it was a great crowd at the event with equally great energy!"

Isaac Hutchinson
Tech Transfer Specialist
J&J

Snapshot of Attending Companies

Adaptimmune · Beam Therapeutics · BioMarin · Bristol Myers Squibb · editas Medicine · ensoma · bluebirdbio · insmed · Intellia Therapeutics · Johnson & Johnson · Jaguar Gene Therapy · Oxford Biomedica · Regeneron · REGENXBIO · SalioGen Therapeutics · sanofi · Sarepta Therapeutics · Solid Biosciences · Spark Therapeutics · Tenaya Therapeutics · ultragenyx pharmaceutical · vaccitech · Vertex

2nd Annual

Gene Therapy Regulatory Affairs

Over 2000 gene therapies are in preclinical and clinical development, and as the FDA announces the development of a 'super office' for therapeutic products to support the significant increase in submissions of gene therapy INDs and BLAs, it's never been so important for gene therapy developers to both understand regulatory bottlenecks and develop solutions to overcome them.

The Gene Therapy Regulatory Affairs Summit brings together regulatory professionals across gene therapy and gene editing to delve into the specific regulatory non-clinical & clinical strategies and CMC requirements from pre-IND through to approval to successfully demonstrate safety and efficacy.

Attendee Breakdown



Attendee Seniority

- Cheif/CXO.....5.7%
- Director.....42%
- Head.....4.7%
- Manager.....10%
- President/VP.....15%
- Project/Team..0.6%
- Scientist.....5%
- Other.....17%

Industry Breakdown

- Pharma.....21%
- Biotech.....53%
- Not for Profit.....6%
- Academic.....4%
- Service Provider.....12%
- Other.....4%

16+
SPEAKERS

40+
COMPANIES

60+
ATTENDEES

77%
LARGE PHARMA & BIOTECH

4

"The quality of speakers was excellent, and the topics were current"

Gene Therapy Event Series
Attendee
Chief Regulatory Officer
Opus Genetics

Snapshot of Attending Companies

4DMT
Advanced Cell & Gene Therapy
ADVERUM BIOTECHNOLOGIES
AstraZeneca
bridgebio
Health Canada
OMEGA THERAPEUTICS
OPUS GENETICS
Pfizer
RareMoon
REGENERON
Sangamo THERAPEUTICS
SOLID BIOSCIENCES
Spark THERAPEUTICS
ultragenyx

2nd Annual
Viral Vector Process Development & Manufacturing Summit

2nd Annual
Viral Vector Formulation & Process Development Summit EUROPE

The 2nd Viral Vector Process Development & Manufacturing Summit will return to Boston in 2024, uniting 130+ pioneering Viral Vector Upstream, Downstream & MSAT experts to supercharge Your AAV, AV & LV Process Development & GMP Manufacturability for a Quality, Accessible Treatments for Patients.

As the only industry-focused summit for viral vector specialists, we will help bridge the gap of up- and downstream viral vector process intensification, enabling rapid scale-up with strengthened analytical capabilities. This is the unique forum to help you advance your mid- and late-stage asset through pipeline with streamlined tech transfer and GMP compliance with optimized COGS.

Be part of this dialogue and must-attend summit to ensure safety and affordability for patients through robust process development and quality of viral vectors!

Attendee Breakdown



Attendee Seniority

- Chief/CXO.....6%
- President/VP.....11%
- Director.....33%
- Head.....19%
- Manager.....17%
- Other.....14%



Industry Breakdown

- Drug Developers.....66%
- Regulatory Agency.....15%
- CDMO.....10%
- Equipment/Service Providers.....9%

30+ SPEAKERS

50+ COMPANIES

150+ ATTENDEES

72% LARGE PHARMA & BIOTECH

4

"Well organized event covering important topics for viral vector manufacturing and analytics. High-quality presentations and engaged audiences. The conference had the right mix of technical content and breaks. I was able to focus on the presentations and had enough time to follow-up with speakers."

Capsida Therapeutics

Snapshot of Attending Companies

2seventybio · Biogen · BIOMARIN · Bristol Myers Squibb · CATAPULT Cell and Gene Therapy · Lilly · Genentech A Member of the Roche Group · GILEAD · gsk · janssen · Kite A GILEAD Company · Lacerta therapeutics · Lonza Pharma & Biotech · MEIRAGTx · MERCK · novo nordisk · Orchard therapeutics · PackGene · Pfizer · Raven biosciences · SAREPTA THERAPEUTICS · SARTORIUS BIA Separations is now part of Sartorius · Spark THERAPEUTICS · Takeda · ThermoFisher SCIENTIFIC · ucb · ultragenyx pharmaceutical · VERTEX

5th Annual

CRISPR 2.0

CRISPR technology is on the brink of transforming treatment for a wide range of diseases. The CRISPR 2.0 Congress showcases the latest and greatest CRISPR tools being developed (including prime editing, base editing, novel nucleases, epigenetic targeting and more) and explores how this expanding CRISPR toolbox is being applied to develop transformative therapeutics.

Uniting 150+ gene editing experts across discovery, R&D, delivery, through to preclinical and clinical development, the meeting addresses the hottest topics in developing and advancing gene editing therapeutics through the pipeline. This includes optimizing in vivo targeting beyond the liver, assessing and measuring off-target effects to demonstrate safety, efficiently delivering increasingly complex CRISPR constructs to target cells, and making larger and more significant gene edits to expand into a wider range of disease indications.



Attendee Breakdown



Attendee Seniority

- C Level 8%
- President/VP 4%
- Director/Haed 26%
- Manager 10%
- Scientist 33%
- Other 19%



Industry Breakdown

- Biotech 57%
- Pharma 11%
- Service Provider 20%
- Academic 10%
- Other 2%

30+ SPEAKERS

75+ COMPANIES

100+ ATTENDEES

68% LARGE PHARMA & BIOTECH

"High quality attendees with very relevant presentations. The speed networking session was excellent."

Andre Miguel
Technical Sales Specialist
Thermo Fisher Scientific

Snapshot of Attending Companies

ALEXION · arbor biotech · be BIOPHARMA · Beam THERAPEUTICS · CARIBOU BIOSCIENCES · CHROMA MEDICINE · CRISPR THERAPEUTICS · editas MEDICINE · elevatebio · Lilly · EMENDO BIOTHERAPEUTICS · epic bio · EXCISION · HARVARD MEDICAL SCHOOL · life edit an elevatebio company · Metagenomi · Massachusetts Institute of Technology · moderna · prime medicine · sanofi · scribe THERAPEUTICS · TUNE THERAPEUTICS · Berkeley UNIVERSITY OF CALIFORNIA · verve THERAPEUTICS

2nd Annual

CRISPR-BASED THERAPY ANALYTICAL DEVELOPMENT



CRISPR-based therapies are becoming increasingly complex as drug developers work to enhance the safety, target specificity and efficiency of their products. With this shift comes a change in analytical methods and tools that must also evolve to effectively characterize different genome edited products that use CRISPR technology.

Given this context, the CRISPR-Based Therapy Analytical Development Summit is bringing together 80+ analytical development experts who are dedicated to the development and implementation of analytical tools that relate specifically to the CRISPR-construct.

Attendee Breakdown



Attendee Seniority

- Cheif 10%
- Director 22%
- Head 4%
- Manager 12%
- President/VP 11%
- Professor 2%
- Project/Team 1%
- Scientist 21%
- Other 17%

Industry Breakdown

- Biotech 45%
- Pharma 14%
- Service Provider 30%
- Academic Organization 11%

16+ SPEAKERS

40+ COMPANIES

60+ ATTENDEES

77% LARGE PHARMA & BIOTECH

4

"An interactive conference with great networking groups."

CRISPR Series Attendee
Associate Director
Moderna

Snapshot of Attending Companies

EXCISION · HARVARD MEDICAL SCHOOL · life edit an elevatebio company · Metagenomi

verve THERAPEUTICS · Berkeley UNIVERSITY OF CALIFORNIA · TUNE THERAPEUTICS · scribe THERAPEUTICS

elevatebio · Lilly · EMENDO BIOTHERAPEUTICS · epic bio

Beam THERAPEUTICS · be BIOPHARMA · arbor biotech · ALEXION

Massachusetts Institute of Technology · moderna · prime medicine · sanofi

editas MEDICINE · CRISPR THERAPEUTICS · CHROMA MEDICINE · CARIBOU BIOSCIENCES

5th Annual
Exosome Based Therapeutic Development Summit



The 6th Exosome Based Therapeutic Development Summit returns as the leading industry forum, uniting key biopharma and academics dedicated to the clinical translation and commercialisation of exosome therapeutics and functional delivery vehicles across oncology, CNS, inflammation, and beyond. Unleash the therapeutic and delivery power of exosomes and EVs next September!

This is the most comprehensive, end-to-end meeting for industry personnel who are looking to fine tune molecular components of exosomes, achieve GMP manufacturing of EVs for clinical applications and successfully deliver payloads to the target tissue by evaluating route of administration to accelerate candidates towards commercialisation.

Join 140+ of your peers to Unlock Native & Engineered Exosomes with Improved Targeting, Optimize Analytics & Achieve GMP Manufacturing for Effective Translation into the Clinic & Towards Commercialization.

This technical forum is uniquely positioned to equip you with both the scientific know-how, and benchmark against your industry peers on their characterization and analytical approaches.

Attendee Breakdown



Attendee Seniority

- C Level/Founder/President/VP 26%
- Director/Head 18%
- Principal Scientist/Lead Investigator 20%
- Professor/Assistant Professor 16%
- Other 20%



Industry Breakdown

- Large Pharma & Biotech 75%
- Research & Academia 13%
- Solution Provider 12%

35+
SPEAKERS

50+
COMPANIES

160+
ATTENDEES

45%
LARGE PHARMA & BIOTECH

4

"Great talks from many different industry and academic perspectives. The overall agenda was comprehensive and gave great insight into the different challenges the EV field is facing as we move towards clinical applications."

Astellas

Snapshot of Attending Companies

abbvie
AEGLE THERAPEUTICS
ARCTURUS therapeutics
astellas
BioXtek Regenerative Therapeutics
brainstorm cell therapeutics
Capricor Therapeutics
CELLS FOR CELLS
COASTAR
EV Therapeutics Immunotherapy EVolved.
EVerZom
EXO Biologics
Lonza
OmniSpirant THERAPEUTICS
Organicell
ReNeuron
RION HEAL FROM WITHIN
Secretome THERAPEUTICS
SHIFTBIO
VERSATOPE Delivering Immunity
Vesigen THERAPEUTICS
YURIA·PHARM

WHY PARTNER?

LOOKING TO BUILD LONG-TERM PARTNERSHIPS WITH THE WORLD'S LEADING GENE THERAPY DRUG DEVELOPERS?

We partner with cutting-edge service providers with capabilities in viral vector manufacturing, analytical methods, translation, diagnostics, clinical trials, commercialization and more.

Our goal is to unite a rapidly accelerating industry to overcome existing challenges in the field, maximize its true potential and meet patients' needs.

If you have relevant capabilities and would like to align your brand with the gene therapy space, contact us to discuss bespoke opportunities to engage our audiences.

Thomas Stockdale
Partnerships Director

Max Wainwright
Partnerships Director

Contact us at:
sponsor@hansonwade.com

Benefits of Partnering

Generate new business leads
by securing valuable face time with key decision-makers during virtual speed networking and pre-organized 1-2-1 meetings

Build brand awareness
and increase market share through pre-conference and at-event advertising

Gain the trust of drug developers
by presenting on the main agenda and positioning yourself as an essential partner for success

Showcase your product
in the exhibition room and give potential customers a hands-on insight into your capabilities

With Thanks To Our Partners

CERTARA
ProtaGene
BioAgilytix
Beckman Coulter Life Sciences
Sartorius
Bio-Rad
Coriolis Pharma
ThermoFisher Scientific
Catalent Paragon Gene Therapy
Forge Biologics
labcorp Drug Development
cytiva
intertek Total Quality. Assured.
ProPharma Group
premier research
Fujifilm Diosynth biotechnologies
GenoSafe
Gyros Protein Technologies
Invitae
InformedDNA
Lonza Pharma & Biotech
Millipore Sigma
AGC Biologics
Malvern Panalytical
Azzur Group
Polyplus transfection
Teknova
Precision for medicine
ADVANCE
PROGEN Making gene therapy better. Together.
Project Farma
Unchained Labs
Center for Breakthrough Medicines
QIAGEN
Repligen
Rho
SCIEX The Power of Precision
Viralgen
Veristat
VGXI Quality...it's in our DNA
Waters The Science of What's Possible.
Wyatt Technology

CASE STUDIES

Find out from your peers why our meetings lie at the heart of their business development strategy.

Discover, in the words of solution providers like you, what makes these events different and why they return year after year to be part of the Gene Therapy Event Series.

SARTORIUS | BIA separations

BIA Separations is now part of Sartorius

When BIA Separations chose to become a partner of our events, what were the main goals you were seeking to achieve?

BIA Separations (BIA) is a leading bio-chromatography development and manufacturing company, providing research and method development services for the purification of large and complex biomolecules.

A major focus for BIA is to address a significant gap in gene-therapy manufacturing capability and supporting the biopharma industry to progress a deep pipeline of gene-therapy drug candidates. It is currently both challenging and expensive to precisely and reproducibly manufacture commercial-scale volumes of viral and non-viral vectors, and also widely recognised that developing the required 'know-how' in-house and at the required pace, is 'make or break' in getting new therapies to market.

By becoming a partner, we want to meet and engage with other experts in gene therapy so we can exchange knowledge, expertise and industry experience.

Why did you feel our gene therapy events were a good solution?

BIA seeks to collaborate with academic researchers, CMOs and biopharmaceutical companies to develop efficient and robust manufacturing processes; refine and scale-up existing protocols; custom develop products for specific applications; and provide the subsequent transfer of critical skills.

These events bring together like minded individuals who are looking to overcome the challenges of bringing new gene therapies to market and ultimately closer to helping patients.

BIA's support has contributed to the production of hundreds of advanced therapy medicinal product batches of early-stage gene-therapies and virus-based cancer therapies, including many currently in mid-stage clinical trials, and two that have been brought successfully to market.

What have been the results of this partnership for BIA Separations' business in gene therapy?

We have had many great discussions and made many very valuable new connections.

We are currently close to striking some new process development contracts based on contacts and discussions facilitated by our involvement in these gene therapy events.

Ales Strancar
Managing Director
BIA Separations



BROUGHT TO YOU BY

hansonwade